{"disease":{"id":"typhoid","name":"Typhoid","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"ampicillin","indication_name":"Paratyphoid fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"chloramphenicol","indication_name":"Paratyphoid fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chlorocidin","generic_name":"CHLORAMPHENICOL","company_name":"Parkedale","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Amphenicol-class Antibacterial","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"chloramphenicol","indication_name":"Typhoid fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chlorocidin","generic_name":"CHLORAMPHENICOL","company_name":"Parkedale","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Amphenicol-class Antibacterial","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Typhoid fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Typhoid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis A and typhoid","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis A and typhoid (oral)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Typhoid (oral)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Typhoid (injectable)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"chloramphenicol-succinate","indication_name":"Typhoid fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chloromycetin","generic_name":"chloramphenicol succinate","company_name":"Parkedale","drug_phase":"marketed","molecular_target":"","drug_class":"Amphenicol-class Antibacterial","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Typhoid fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Typhoid fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Typhoid fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ofloxacine","indication_name":"Typhoid fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05500482","title":"Vellore Typhoid Vaccine Impact Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":72400,"lead_sponsor_name":"Christian Medical College, Vellore, India","has_results":false},{"nct_id":"NCT05562102","title":"TyVECO: Surveillance Protocol","phase":"","overall_status":"UNKNOWN","enrollment_count":48000,"lead_sponsor_name":"International Vaccine Institute","has_results":false},{"nct_id":"NCT03299426","title":"Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30000,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT04852185","title":"Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":23000,"lead_sponsor_name":"International Vaccine Institute","has_results":false},{"nct_id":"NCT03554213","title":"Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India","phase":"","overall_status":"COMPLETED","enrollment_count":17292,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT06757283","title":"ZyVac-TCV Bangladesh Study","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","has_results":false},{"nct_id":"NCT04801602","title":"Commercial Typhoid Tests Validation Trial","phase":"","overall_status":"COMPLETED","enrollment_count":3091,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT04349826","title":"The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2150,"lead_sponsor_name":"Oxford University Clinical Research Unit, Vietnam","has_results":false},{"nct_id":"NCT04850677","title":"Treating Non-typhoidal Salmonella Bloodstream Infections in Children Under Five in DR Congo: a Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":1884,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT04204096","title":"Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"International Vaccine Institute","has_results":false},{"nct_id":"NCT02947295","title":"Global Genomic and Proteomic Profiling of African Children With Typhoid Fever","phase":"","overall_status":"COMPLETED","enrollment_count":969,"lead_sponsor_name":"University of Nebraska","has_results":false},{"nct_id":"NCT02391909","title":"Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers","phase":"","overall_status":"COMPLETED","enrollment_count":855,"lead_sponsor_name":"Bavarian Nordic","has_results":false},{"nct_id":"NCT04289688","title":"Health Itinerary of Young Children With Suspected Bloodstream Infection in Kisantu General Referral Hospital, DR Congo","phase":"","overall_status":"COMPLETED","enrollment_count":784,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT05475379","title":"Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":630,"lead_sponsor_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","has_results":false},{"nct_id":"NCT06921460","title":"Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":624,"lead_sponsor_name":"PT Bio Farma","has_results":false},{"nct_id":"NCT04235361","title":"Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University of Stirling","has_results":false},{"nct_id":"NCT04830371","title":"Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"EuBiologics Co.,Ltd","has_results":false},{"nct_id":"NCT05579821","title":"Evaluation Study of DPP® Typhoid Assay","phase":"","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT07150065","title":"Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"Avicenna Medical College Lahore","has_results":false},{"nct_id":"NCT03527355","title":"Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":285,"lead_sponsor_name":"International Vaccine Institute","has_results":false},{"nct_id":"NCT03614533","title":"Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT03705585","title":"CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT02645032","title":"Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"International Vaccine Institute","has_results":false},{"nct_id":"NCT04154722","title":"Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Ziauddin University","has_results":false},{"nct_id":"NCT05613205","title":"Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT07445282","title":"This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Sheikh Zayed Medical College","has_results":false},{"nct_id":"NCT03970304","title":"CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":87,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT05870150","title":"Challenge Non-Typhoidal Salmonella (CHANTS) Study","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Imperial College Healthcare NHS Trust","has_results":false},{"nct_id":"NCT03956524","title":"Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"EuBiologics Co.,Ltd","has_results":false},{"nct_id":"NCT06104345","title":"Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Helsinki University Central Hospital","has_results":false},{"nct_id":"NCT04543877","title":"WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"USDA, Western Human Nutrition Research Center","has_results":false},{"nct_id":"NCT03312699","title":"Effects of Aging on Primary and Secondary Vaccine Responses","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT03926455","title":"Safety and Immunogenicity of Typhax, a Typhoid Vaccine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Matrivax Research and Development Corporation","has_results":false},{"nct_id":"NCT03494101","title":"Interaction Between Non-typhoid Salmonella, Host Microbiota, and Immune System During Acute Infection and Remission","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT06546982","title":"Diagnosis and Staging of Typhoid Fever Using Surface-enhanced Raman Spectroscopy Liquid Biopsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"University Hospital, Aachen","has_results":false},{"nct_id":"NCT03600025","title":"Cellular Immune Responses in Typhoid Fever Patients and Vaccinees","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","has_results":false},{"nct_id":"NCT00277147","title":"Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT04083950","title":"Induction of Gut Permeability by an Oral Vaccine","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"USDA, Western Human Nutrition Research Center","has_results":false},{"nct_id":"NCT00386789","title":"Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age","phase":"","overall_status":"COMPLETED","enrollment_count":0,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false}],"total":39},"guidelines":[],"source":"Drug Landscape verified database"}